MannKind Corporation (MNKD) shares plummeted approximately 16% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.

The biopharmaceutical company reported a net loss of $0.05 per share for the quarter ended December 31, 2025, which fell short of analyst expectations. According to an earnings summary, the mean expectation of eight analysts was for earnings of one cent per share, representing a significant miss. The company's adjusted loss of 5 cents per share also contrasted with earnings of 3 cents per share in the same quarter last year.

While MannKind's quarterly revenue of $112 million exceeded the analyst estimate of $97.6 million, the earnings disappointment appears to have driven the sharp sell-off. The company reported a Q4 operating loss of $7.687 million and a net loss of $15.948 million, contributing to negative investor sentiment despite revenue growth.